 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism, as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Waltham, MA.

Current Price	$29.14
Prev Close	$29.20
Open	$29.17
Dividend Yield	N/A
50-Day Moving Average	$23.15
Beta	0.00
Avg. Volume	823,610.50
PE Ratio	-12.67

52-Week High	$43.15
52-Week Low	$10.53
Market Capitalization	$1.27B
EPS	-$2.29
Price to Book	2.45
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-11.18

CINC CinCor Pharma Inc

About

Feed

Fundamentals

News